argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.
| Revenue (Most Recent Fiscal Year) | $2.25B |
| Net Income (Most Recent Fiscal Year) | $833.04M |
| PE Ratio (Current Year Earnings Estimate) | 44.48 |
| PE Ratio (Trailing 12 Months) | 94.68 |
| PEG Ratio (Long Term Growth Estimate) | 1.03 |
| Price to Sales Ratio (Trailing 12 Months) | 13.10 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.28 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 191.23 |
| Pre-Tax Margin (Trailing 12 Months) | 13.67% |
| Net Margin (Trailing 12 Months) | 40.20% |
| Return on Equity (Trailing 12 Months) | 16.15% |
| Return on Assets (Trailing 12 Months) | 14.33% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.29 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.68 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.44 |
| Book Value per Share (Most Recent Fiscal Quarter) | $90.49 |
| Earnings per Share (Most Recent Fiscal Quarter) | $2.58 |
| Earnings per Share (Most Recent Fiscal Year) | $2.57 |
| Diluted Earnings per Share (Trailing 12 Months) | $16.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 61.06M |
| Free Float | 59.58M |
| Market Capitalization | $34.69B |
| Average Volume (Last 20 Days) | 0.28M |
| Beta (Past 60 Months) | 0.39 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.43% |
| Percentage Held By Institutions (Latest 13F Reports) | 60.32% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |